Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 8;15(18):3913.
doi: 10.3390/nu15183913.

The Regulation and Secretion of Glucagon in Response to Nutrient Composition: Unraveling Their Intricate Mechanisms

Jiudan Zhang  1   2 , Yang Zheng  1 , Lisa Martens  2   3 , Andreas F H Pfeiffer  2
Affiliations
Review

The Regulation and Secretion of Glucagon in Response to Nutrient Composition: Unraveling Their Intricate Mechanisms

Jiudan Zhang et al. Nutrients. .

Abstract

Glucagon was initially regarded as a hyperglycemic substance; however, recent research has revealed its broader role in metabolism, encompassing effects on glucose, amino acids (AAs), and lipid metabolism. Notably, the interplay of glucagon with nutrient intake, particularly of AAs, and non-nutrient components is central to its secretion. Fasting and postprandial hyperglucagonemia have long been linked to the development and progression of type 2 diabetes (T2DM). However, recent studies have brought to light the positive impact of glucagon agonists on lipid metabolism and energy homeostasis. This review explores the multifaceted actions of glucagon, focusing on its regulation, signaling pathways, and effects on glucose, AAs, and lipid metabolism. The interplay between glucagon and other hormones, including insulin and incretins, is examined to provide a mechanistic understanding of its functions. Notably, the liver-α-cell axis, which involves glucagon and amino acids, emerges as a critical aspect of metabolic regulation. The dysregulation of glucagon secretion and its impact on conditions such as T2DM are discussed. The review highlights the potential therapeutic applications of targeting the glucagon pathway in the treatment of metabolic disorders.

Keywords: amino acid; glucagon; glucose; hyperglucagonemia; lipid.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Glucagon receptors on multiple organs and the stimulation/inhibition of glucagon release. (This graph was generated with www.biorender.de).
Figure 2
Figure 2
The underlying mechanisms of glucagon stimulation to glucose, amino acids, and fatty acids (↑increase). (This graph is generated with www.biorender.de).
See this image and copyright information in PMC

References

    1. Ricketts H.T. Glucagon: Molecular Physiology, Clinical and Therapeutic Implications. JAMA. 1973;224:403. doi: 10.1001/jama.1973.03220160053031. - DOI
    1. Murlin J.R., Clough H.D., Gibbs C.B.F., Stokes A.M. Aqueous Extracts of Pancreas. J. Biol. Chem. 1923;56:253–296. doi: 10.1016/S0021-9258(18)85619-8. - DOI
    1. Sutherland E.W., de Duve C. Origin and Distribution of the Hyperglycemic-Glycogenolytic Factor of the Pancreas. J. Biol. Chem. 1948;175:663–674. doi: 10.1016/S0021-9258(18)57183-0. - DOI - PubMed
    1. Sasaki H., Ebitani I., Tominaga M., Yamatani K., Yawata Y., Hara M. Glucagon-like substance in the canine brain. Endocrinol. Jpn. 1980;27((Suppl. 1)):135–140. doi: 10.1507/endocrj1954.27.Supplement_135. - DOI - PubMed
    1. Guzman C.B., Zhang X.M., Liu R., Regev A., Shankar S., Garhyan P., Pillai S.G., Kazda C., Chalasani N., Hardy T.A. Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. Diabetes Obes. Metab. 2017;19:1521–1528. doi: 10.1111/dom.12958. - DOI - PubMed